MBP8298

Parent company: BioMS

Administered intravenously every six months.

This peptide is a synthetic fragment of myelin basic protein (MBP). It replicates the site on the MBP molecule that is believed to be a target of attack by cells of the immune system, in 65 to 75 percent of all people with MS. It is believed to induce or restore immunologic tolerance to attack.

Phase I and II trials showed that, versus placebo, MBP8298 was safe and tolerable, and delayed the median time to disease progression by five years in people with SPMS.

MINDSET-01 is an ongoing Phase II trial with RRMS patients in Europe, comparing MBP8298 versus placebo.

MAESTRO-03 is a phase III trial in 510 people with SPMS who will be followed for two years. Its primary outcome measure is time to progression as measured by EDSS; secondary measures include the degree of change in EDSS and MRI changes.